Pfizer (PFE) Non Operating Income (2010 - 2026)

Pfizer (PFE) has 17 years of Non Operating Income data on file, last reported at -$861.0 million in Q1 2026.

• Non Operating Income for Q1 2026 came in at -$861.0 million, up 9.65% year-over-year; the trailing twelve-month figure through Mar 2026 was -$6.6 billion (down 122.29% YoY), and the FY2025 annual result was -$6.7 billion, down 53.24% from the prior year.
• Non Operating Income improved to -$861.0 million in Q1 2026 per PFE's latest filing, from -$4.5 billion in the prior quarter.
• Over five years, Non Operating Income peaked at $159.0 million in Q4 2023 and troughed at -$4.5 billion in Q4 2025.
• A 5-year average of -$726.6 million and a median of -$517.0 million in 2025 frame the typical range for Non Operating Income.
• The sharpest annual moves came in 2023 and 2024: Non Operating Income surged 109.72% in 2023, then plunged 1576.0% in 2024.
• A 5-year view of Non Operating Income shows it stood at $59.0 million in 2022, then soared by 169.49% to $159.0 million in 2023, then tumbled by 252.83% to -$243.0 million in 2024, then plunged by 1757.61% to -$4.5 billion in 2025, then soared by 80.93% to -$861.0 million in 2026.
• Business Quant data shows PFE's Non Operating Income at -$861.0 million in Q1 2026, -$4.5 billion in Q4 2025, and -$517.0 million in Q3 2025.